China's BCI Breakthrough: World-First Approval For Hand-Movement Device

China's drug regulator approved the world's first commercial brain-computer interface (BCI) system, targeting movement restoration for paralytic patients. Developed by Borui Kang Medical Technology, the device involves minimal electrode implantation to improve quality of life by enhancing hand movement and communication, aligning with Beijing's industry advancement goals.

In a groundbreaking move, China's drug regulator announced on Friday the approval of a brain-computer interface (BCI) system designed to help restore hand movement. This marks the first global approval for such a device aimed at commercial use.

The innovative device was developed by Borui Kang Medical Technology and focuses on aiding individuals with quadriplegia resulting from cervical spinal cord injuries. The system involves a minimally invasive procedure where electrodes are inserted directly into the brain, utilizing wireless technology to enhance hand-grasping ability through a special glove.

This development is significant as BCI technology was prioritized in Beijing's recent industrial strategy, with ambitions for widespread public use within the next few years. The approval positions China in competition with U.S. startups like Neuralink, with hopes of improving the quality of life for eligible spinal cord injury patients.

(With inputs from agencies.)